Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ITI-1284 for Psychosis Associated with Alzheimer’s Disease
2024-513035-25-00Phase 2Authorised
- Sponsor
- Intra-Cellular Therapies
- Start
- Jul 2025
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 2, randomised, double-blind trial in Alzheimer's disease psychosis (ADP) comparing ITI-1284 flexible-dose with Placebo (2 arms). Primary endpoint: Change in BEHAVE-AD psychosis subscale score from baseline to end of Week 6. Planned start Jul 2025; status: authorised.
02
Drugs
deulumateperone
03
Conditions
Alzheimer's disease psychosis (ADP)
Beyond the preview
Go deeper on 2024-513035-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513035-25-00.